Core Viewpoint - The investigation by Halper Sadeh LLC focuses on the fairness of the sale of Confluent, Inc. to IBM at $31.00 per share for Confluent shareholders [1]. Group 1: Investigation Details - The investigation examines whether Confluent and its board violated federal securities laws and/or breached fiduciary duties by not obtaining the best possible consideration for shareholders [2]. - It questions if IBM is underpaying for Confluent and whether all material information necessary for shareholders to assess the merger consideration was disclosed [2]. Group 2: Potential Actions - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other relief related to the proposed transaction [3]. - The firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees or expenses [3].

The technology giant announced its intent to acquire Confluent for $11 billion. It's a play on the data required for AI. ...

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Cemtrex, Inc. (CETX) has increased by 284% to $11.79 - Treasure Global Inc. (TGL) has risen by 135% to $59.83 - Top Wealth Group Holding Limited (TWG) is up 95% at $11.73 - Fulcrum Therapeutics, Inc. (FULC) has gained 49% to $13.29 - MetaVia Inc. (MTVA) is up 33% at $10.90 - Kymera Therapeutics, Inc. (KYMR) has increased by 31% to $87.58 - Confluent, Inc. (CFLT) is up 27% at $29.40 - Immix Biopharma, Inc. (IMMX) has risen by 23% to $6.85 - Nurix Therapeutics, Inc. (NRIX) is up 18% at $21.46 - SU Group Holdings Limited (SUGP) has increased by 15% to $6.44 [3] Premarket Losers - SMX (Security Matters) Public Limited Company (SMX) has decreased by 27% to $242.01 - Meihua International Medical Technologies Co., Ltd. (MHUA) is down 27% at $10.20 - Polyrizon Ltd. (PLRZ) has declined by 16% to $10.90 - Fly-E Group, Inc. (FLYE) is down 16% at $6.90 - Sensei Biotherapeutics, Inc. (SNSE) has decreased by 14% to $8.29 - Kentucky First Federal Bancorp (KFFB) is down 10% at $4.00 - Arteris, Inc. (AIP) has declined by 7% to $16.27 - Fusion Fuel Green PLC (HTOO) is down 6% at $3.89 - Kamada Ltd. (KMDA) has decreased by 5% to $6.69 - iOThree Limited (IOTR) is down 5% at $3.11 [4]

*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet. IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC. ©2025 Investor's Business Daily, LLC. All Rights Reserved. Terms of Use Privacy Notice Accessibility About Us Reviews Site Map Your Ad Choices Advertising C ...

Dec 8 (Reuters) - IBM said on Monday it will buy data infrastructure company Confluent in a deal valued at $11 billion, ramping ​up its cloud-computing offerings to capitalize on an AI-driven demand boom. Big ‌Blue, under CEO Arvind Krishna, has doubled down on M&As to beef up its cloud ‌and software business - a high-growth, high-margin area - as customers invest to upgrade their digital infrastructure to house complex artificial intelligence applications. Mountain View, California-based Confluent provi ...

IBM said on Monday it will buy data infrastructure company Confluent in a deal valued at $11 billion, ramping up its cloud-computing offerings to capitalize on an AI-driven demand boom. ...

Core Points - IBM is acquiring data streaming platform Confluent for $11 billion, with the transaction expected to close by mid-2026 [1][2] - Confluent's shares increased by 26% in premarket trading following the announcement, while IBM's stock decreased by approximately 1% [1] - IBM will pay $31 per share in cash for all issued and outstanding common shares of Confluent [1] Company Strategy - The acquisition aims to enhance IBM's offerings by providing a smart data platform for enterprise IT, specifically designed for AI applications [2]

Shares of Confluent surged nearly 28% in premarket trading on Monday after the Wall Street Journal reported that IBM is in advanced discussions to acquire the data-streaming platform for about $11 bil... ...

Company Acquisition - IBM is in advanced negotiations to acquire Confluent, a real-time data infrastructure company, in a deal valued at approximately $11 billion [2][3] - The acquisition aims to enhance IBM's capabilities in hybrid cloud and AI by integrating Confluent's data streaming technology into its analytics and enterprise cloud services, positioning IBM more competitively against AWS, Azure, and Google Cloud [3] Market Position and Strategy - Confluent has a market capitalization exceeding $8 billion and serves customers in finance, retail, and other data-intensive sectors [4] - This potential acquisition follows IBM's recent purchase of HashiCorp, indicating a trend of consolidation in AI-driven enterprise software and cloud infrastructure [4] Pharmaceutical Developments - Eli Lilly, Pfizer, and Johnson & Johnson have been included in China's first innovative drug catalog for private insurance, which aims to improve access to high-cost therapies [4][5] - The catalog features 19 medicines targeting conditions such as cancer, Alzheimer's, and rare genetic disorders, with Eli Lilly's diabetes drug Mounjaro set to be added to China's state-run health insurance scheme starting January 1 [5][6] - The new program allows for negotiated discounts of 15% to 50% on drugs that are too expensive for state insurance, potentially increasing pharmaceutical margins in China's aging market [6]

Group 1: Acquisition of Confluent - IBM is in advanced discussions to acquire Confluent for approximately $11 billion, as reported by the Wall Street Journal [1] - Confluent operates a cloud-native platform that processes large streams of real-time data, enabling businesses to respond intelligently to operational events [2] - Confluent's market capitalization is around $8.09 billion, while IBM's valuation is approximately $287.84 billion [3] Group 2: Financial Performance - Confluent reported subscription revenue of $286 million for Q3 and anticipates revenue of $295.5 million to $296.5 million for Q4 [2] - The interest in acquiring Confluent is driven by increased demand for data infrastructure, particularly due to the corporate push towards generative AI [4] Group 3: Regulatory Developments - IBM has been designated as a critical ICT provider under the EU's Digital Operational Resilience Act (DORA) [5] - This designation requires IBM to comply with operational resilience standards and regulatory obligations set by European Supervisory Authorities [7] - IBM will collaborate with these authorities to meet the operational and technical resilience requirements essential for Europe's financial system [6]